Prognostic significance of consolidation-to-tumor ratio in stage IA solid predominant non-mucinous adenocarcinoma: a paradigm for risk stratification [0.03%]
以实性为主非粘液性肺腺癌IA期的巩固区与结节比：风险分层新指标
Yura Ahn,Geun Dong Lee,SeHoon Choi et al.
Yura Ahn et al.
Objective: The optimal consolidation-to-tumor ratio (CTR) cutoff for survival stratification in radiologically solid-predominant adenocarcinoma (CTR > 0.5) remains unclear. This study aimed to evaluate the prognostic sign...
Immunotherapy in uncommon EGFR-mutant NSCLC: Revisiting a therapeutic gray zone [0.03%]
罕见EGFR突变型NSCLC的免疫治疗：重新审视一个治疗的灰色区域
Jun Hyeok Lim,Woo Kyung Ryu,Jeong-Seon Ryu
Jun Hyeok Lim
Response to the letter of Peng Bai and Jun Zhang on Cost-effectiveness of Adjuvant Alectinib in ALK-positive NSCLC-Considerations for Broader Applicability [0.03%]
彭摆和张俊来信《关于ALK阳性非小细胞肺癌辅助治疗药物阿雷替尼的成本效益的考虑》的回复
Romain Supiot,Léopoldine du Manoir de Juaye,Christos Chouaid
Romain Supiot
Proteomic profiling of early-stage non-small cell lung cancer identifies a high-performance protein signature associated with postoperative recurrence [0.03%]
基于早中期肺癌蛋白质组学的蛋白标志物研究
Ying Huang,Qiuhua Deng,Jie Li et al.
Ying Huang et al.
Background: The 5-year recurrence rate remains significantly high (∼30 %) in patients with early-stage Non-Small Cell Lung Cancer (NSCLC), even after complete tumor resection. Recurrence prediction primarily relies on pa...
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC [0.03%]
靶向HGF/MET和CXCL1/CXCR2通路可克服KRASG12C抑制剂在NSCLC中的耐药性
A Cavazzoni,M Pagano Mariano,A Palladini et al.
A Cavazzoni et al.
Background: Resistance to KRASG12C inhibitors sotorasib and adagrasib, approved for KRASG12C-mutant advanced Non-Small Cell Lung Cancer (NSCLC), involves multiple subclonal events, raising significant concerns about overc...
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) [0.03%]
奥希替尼减量与EGFR突变阳性一线转移性非小细胞肺癌患者的生存期关系 исследование
Adam Barsouk,Alec Heidlauf,Keshav Goel et al.
Adam Barsouk et al.
Introduction: Osimertinib has become standard of carein 1 LEGFR-mutated(mt)mNSCLC following the FLAURA trial.However, limited data are available on the effect of osimertinib dose-reductionon outcomes compared tofull-dose....
Immune-related disorders in patients with Thymic Epithelial Tumors: from pathogenesis to tailored interventions [0.03%]
胸腺上皮肿瘤患者的免疫相关性疾病：从发病机制到个体化治疗
Erica Pietroluongo,Giovannella Palmieri,Paolo Antonio Ascierto et al.
Erica Pietroluongo et al.
Background and objective: Thymic epithelial tumors (TETs) are rare malignancies often associated with immunological disorders (IDs), including autoimmune diseases and paraneoplastic syndromes. Myasthenia gravis (MG) is th...
Diagnostic performance of monarch robotic bronchoscopy with and without mobile cone-beam CT support [0.03%]
Monarch机器人支气管镜联合移动式锥形束CT的诊断性能评估
Jingjing Chen,Dakota McNierney,Joe G Zein et al.
Jingjing Chen et al.
Background: Robotic-assisted bronchoscopy (RAB) is limited by CT-to-body divergence. Cone-beam CT (CBCT) may enhance tool-to-lesion alignment and diagnostic yield (DY), but the benefit of integrating mobile CBCT (mCBCT) i...
Monireh Sadat Seyyedsalehi,Massimiliano Cani,Qian Wang et al.
Monireh Sadat Seyyedsalehi et al.
Lung cancer (LC) remains the leading cause of cancer-related mortality among women worldwide. Compared to men, LC in women presents distinct epidemiologic, biological, and clinical characteristics. A large proportion of LC cases in women oc...